CaroleBMillerMD

Oncology • Baltimore, MD

Physician

Join to view full profile

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Miller's full profile

Already have an account?

Office
900 Caton Ave
Baltimore, MD 21229
Phone+1 410-368-2910

Fax+1 667-234-3517
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
Johns Hopkins UniversityResidency, Internal Medicine, 1984 - 1987
University of Maryland School of MedicineClass of 1984

Certifications & Licensure

MD State Medical License 1987 - 2025
FL State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Start of enrollment: 2018 Nov 22
Active, not recruiting
Phase 2
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.
John Cafardi, Carole Miller, Howard Terebelo, Chad Tewell, Sadia Benzaquen, David Park, Pamela Egan, Daniel Lebovic, Kristen Pettit, Eric Whitman, Douglas Tremblay, Jo...> ;JAMA Network Open. 2022 Dec 1
3 citations
Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration.
Wesley V Cain, Anne M Sill, Vinod Solipuram, John J Weiss, Carole B Miller, Peter F Jelsma> ;Advances in Hematology. 2022 Jan 1
51 citations
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklos Egyed, Claire N. Harrison, Abdulraheem Yacoub, Alessandro M. Vannucchi, Adam J. Mead, Jean-Jacqu...> ;Blood Advances. 2020 Nov 24
70 citations
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark ...> ;Blood Advances. 2020 Sep 22
21 citations
Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.
Iris R Hartley, Carole B. Miller, Georgios Z. Papadakis, Clemens Bergwitz, Jaydira Del Rivero, Jenny E Blau, Pablo Florenzano, Jason A Berglund, Jing Tassone, Kelly L ...> ;The New England Journal of Medicine. 2020 Sep 9
70 citations
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, Fabrizio Pane, Tamás Masszi, Claire N. Harrison, Ruben A. Mesa, Carole B. Miller, Francesco Passamonti, Simon Dur...> ;The Lancet. Haematology. 2020 Jan 23
173 citations
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, Scott A. Tetreault, Sarit Assouline, Jiri Mayer, Michele Merli, Scott D. Lunin, Andrew R. Pettitt, Zoltán Zsolt Nagy...> ;Journal of Clinical Oncology. 2019 Feb 11
1 citations
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N. Harrison, Martin Griesshammer, Carole B. Miller, Tamás Masszi, Francesco Passamonti, Pierre Zachee, Simon Durrant, Fabrizio Pane, Paola Guglielmelli, Srdan V...> ;British Journal of Haematology. 2018 Jul 1
17 citations
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I
Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek> ;Clinical Lymphoma, Myeloma & Leukemia. 2014 Dec 6
301 citations
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E...> ;Journal of Hematology & Oncology. 2017 Feb 22
16 citations
Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy
Srdan Verstovsek, Claire N. Harrison, Jean-Jacques Kiladjian, Carole B. Miller, Ahmad Naim, Dilan Paranagama, Dany Habr, Alessandro M. Vannucchi> ;Leukemia Research. 2017 May 1
49 citations
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United S...
Ruben A. Mesa, Carole B. Miller, Maureen Thyne, James K. Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan Paranagama, David G. Dubinski, Ahmad Na...> ;Cancer. 2017 Feb 1
4 citations
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
Sikander Ailawadhi, Luke P. Akard, Carole B. Miller, Anand Jillella, Daniel J. DeAngelo, Solveig G. Ericson, Felice P. Lin, Ghulam Warsi, Jerald P. Radich> ;Therapeutic Advances in Hematology. 2017 Jan 1
27 citations
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients with CML-CP: The ENRICH Study
Jorge E. Cortes, Jeffrey H. Lipton, Carole B. Miller, Lambert Busque, Luke P. Akard, Javier Pinilla-Ibarz, Christopher Hunt Keir, Ghulam Warsi, Felice P. Lin, Michael ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2016 May 1
124 citations
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Ke...> ;Haematologica. 2016 Jul 1
121 citations
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Ruben A. Mesa, Carole B. Miller, Maureen Thyne, James K. Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan Paranagama, David G. Dubinski, John Boy...> ;BMC Cancer. 2016 Feb 27
80 citations
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, ...> ;Haematologica. 2015 Apr 1
33 citations
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard S. Levy, Andres Siulnik, Vikas Gupta, Mahmudul K...> ;Haematologica. 2014 Feb 1
52 citations
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, ...> ;Haematologica. 2013 Dec 1
75 citations
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;British Journal of Haematology. 2013 May 1
150 citations
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John Catalano, Michael W. Deininger, Alan L. Shields, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, J...> ;Journal of Clinical Oncology. 2013 Apr 1
1424 citations
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;The New England Journal of Medicine. 2012 Mar 1
75 citations
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
B. D. Smith, Yvette L. Kasamon, Jeanne Kowalski, Christopher D. Gocke, Kathleen M. Murphy, Carole B. Miller, Elizabeth Garrett-Mayer, Hua Ling Tsai, Lu Qin, Christina ...> ;Clinical Cancer Research. 2010 Jan 1
131 citations
Circulating clonotypic B cells in classic Hodgkin lymphoma.
Richard J. Jones, Christopher D. Gocke, Yvette L. Kasamon, Carole B. Miller, Brandy Perkins, James Barber, Milada S. Vala, Jonathan M. Gerber, Lan L. Gellert, Mark J. ...> ;Blood. 2009 Jun 4
7 citations
Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT.
Ephraim J. Fuchs, Leo Luznik, Javier Bolaños-Meade, Carole B. Miller, Robert A. Brodsky, Richard F. Ambinder, Richard J. Jones> ;Bone Marrow Transplantation. 2009 Jan 12
Join now to see all

Abstracts/Posters

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
Carole B. Miller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intole...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018